Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Biomed Pharmacother. 2021 Sep 21;143:112172. doi: 10.1016/j.biopha.2021.112172

Figure 6.

Figure 6.

Treprostinil restores hepatic ATP and ATP synthase levels. (A) Hepatic ATP levels at 6-hours post-reperfusion measured by bioluminescent assay; (B) ATP synthase subunits at 24-hours post-reperfusion measured by SWATH-MS based proteomics, normalized to Gapdh, and expressed as fold-change over control. Data represented are mean ± SEM. *P<0.05, **P<0.01, ***P<0.001 vs. sham; ϕP<0.05 vs. IRI-placebo (n = 4–6/group). One- or two-way ANOVA, Tukey’s multiple comparisons test. ATP: Adenosine triphosphate; SWATH-MS: Sequential windowed acquisition of all theoretical fragment ion mass spectra; Atp5f1c: ATP synthase F1 subunit gamma; Atp5f1d: ATP synthase F1 subunit delta; Atp5i: ATP synthase subunit e; Atp5j2: ATP synthase subunit f; Atp5l: ATP synthase subunit g; Atp5o: ATP synthase subunit o; CTRL: Control; PLB: IRI-placebo; TRE: IRI-treprostinil.